Evaluation of the da Vinci single-port system in colorectal cancer surgery: a scoping review
Authors:
- 5 October 2024
- journal article
- review article
- Published by Springer Nature in Updates in Surgery
- Vol. 76 (7) , 2515-2520
Abstract
Minimally invasive surgery for the treatment of colon and rectal cancer has gained popularity due to its association with reduced postoperative pain, shorter hospital stays, and quicker recovery. The Da Vinci Single-Port (SP) System combines single-port laparoscopy with robotic assistance. This scoping review aims to evaluate the safety and short-term postoperative outcomes of utilizing the Da Vinci SP platform in colorectal cancer surgery. A scoping review was conducted adhering to the PRISMA-ScR guidelines. Data were collected from PubMed, Embase, and the Web of Science Library as of December 22, 2023. Studies were screened and selected based on predefined criteria, focusing on the application of the SP robotic system in colorectal procedures. Data extraction included demographics, surgical details, intraoperative and postoperative outcomes. A narrative summary of the results was provided due to the heterogeneity in study designs. From an initial 2312 articles, 22 studies were selected for analysis, encompassing 465 patients undergoing robotic SP colorectal surgeries. Of these, 384 (82.6%) had a cancer diagnosis. The median age was 65 years, with approximately 60% being male. The median operative time was 225 min, with docking times averaging 12–20 min. Conversion to multi-port laparoscopy occurred in 4.2% of cases, with no conversions to open surgery. Mean intraoperative blood loss ranged from 50 to 150 ml. The mean number of lymph nodes retrieved ranged from 15 to 28. A diverting ileostomy was constructed in 20.3% of patients. Median times to flatus and soft diet were 2.5 and 3 days, respectively, with hospital stays ranging from 3 to 11 days. Perioperative complications occurred in 15.1% of patients, including wound infections (5.1%), anastomotic leakage (3.7%), and postoperative ileus (2.8%). Negative margin status (R0 resection) was achieved in 95% of cases. The Da Vinci SP robotic platform demonstrates promising safety and effectiveness in colorectal cancer surgery. It achieves high rates of successful oncological resection, adequate lymph node retrieval, and minimal intraoperative blood loss. Postoperative outcomes indicate quicker recovery times and manageable complication rates. However, longer follow-up studies are necessary to fully assess recurrence rates and long-term survival benefits associated with this innovative surgical approach.Keywords
This publication has 37 references indexed in Scilit:
- Da Vinci single-port robotic system current application and future perspective in general surgery: A scoping reviewSurgical Endoscopy, 2024
- Single‐port laparoscopic versus single‐port robotic right hemicolectomy: Postoperative short‐term outcomesThe International Journal of Medical Robotics and Computer Assisted Surgery, 2023
- SP rTaTME: initial clinical experience with single-port robotic transanal total mesorectal excision (SP rTaTME)Techniques in Coloproctology, 2021
- Initial clinical experience with Single-Port robotic (SP r) left colectomy using the SP surgical system: description of the techniqueSurgical Endoscopy, 2020
- Single-port robotic transanal minimally invasive surgery (SPR-TAMIS) approach to local excision of rectal tumorsTechniques in Coloproctology, 2020
- rSILS: initial clinical experience with single-port robotic (SPr) right colectomyTechniques in Coloproctology, 2020
- Initial clinical experience of single‐incision robotic colorectal surgery with da Vinci SP platformThe International Journal of Medical Robotics and Computer Assisted Surgery, 2020
- Single-port robotic left colectomy: first clinical experience using the SP robot (rSILS)Techniques in Coloproctology, 2019
- Robotic Single‐Port Platform in General, Urologic, and Gynecologic Surgeries: A Systematic Review of the Literature and Meta‐analysisWorld Journal of Surgery, 2019
- Identification of 12 or more lymph nodes in resected colon cancer specimens as an indicator of quality performanceCancer, 2009